New protocol aims to save more premature babies from severe complications
NCT ID NCT05248477
First seen Nov 20, 2025 · Last updated Jun 20, 2026 · Updated 21 times
Summary
This study tests a new care protocol (EXPRIM) for extremely preterm infants born between 22 and 26 weeks. The protocol involves early counseling, standardized steroid use, and team-based decisions. Researchers will compare survival without severe health problems in 2377 babies across multiple hospitals. The goal is to see if this organized approach improves outcomes compared to usual care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWBORN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Cochin
Paris, 75014, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
new care protocol (EXPRIM protocol)
What this could lead to
If successful, this could establish a better standard of care for extremely preterm infants, reducing severe complications like brain bleeding or lung disease.
What could go wrong
This is a large trial but tests a complex organizational change, not a drug. Results depend on how well hospitals adopt the protocol, and benefits may vary across centers.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.